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Abstract: Research on morbillivirus infections has led to exciting developments in recent 
years. Global measles vaccination coverage has increased, resulting in a significant reduction 
in measles mortality. In 2011 rinderpest virus was declared globally eradicated – only the 
second virus to be eradicated by targeted vaccination. Identification of new cellular receptors 
and implementation of recombinant viruses expressing fluorescent proteins in a range of 
model systems have provided fundamental new insights into the pathogenesis of 
morbilliviruses, and their interactions with the host immune system. Nevertheless, both new 
and well-studied morbilliviruses are associated with significant disease in wildlife and 
domestic animals. This illustrates the need for robust surveillance and a strategic focus on 
barriers that restrict cross-species transmission. Recent and ongoing measles outbreaks also 
demonstrate that maintenance of high vaccination coverage for these highly infectious agents 
is critical. This introduction briefly summarizes the most important current research topics 
in this field. 
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1. Introduction 
The genus Morbillivirus belongs to the virus family Paramyxoviridae, a group of enveloped viruses 
with non-segmented, negative strand RNA genomes. It contains viruses that are highly infectious, spread 
via the respiratory route, cause profound immune suppression, and have a propensity to cause large 
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outbreaks associated with high morbidity and mortality in previously unexposed populations.  
In populations with endemic virus circulation, the epidemiology changes to that of a childhood disease, 
as hosts that survive the infection normally develop lifelong immunity.  
Measles virus (MV) is the prototype morbillivirus, and causes disease in primates. Rinderpest virus 
(RPV) is closely related to MV and used to cause severe disease in cattle. Other viruses in the genus 
Morbillivirus include peste des petits ruminants virus (PPRV), which causes disease in small ruminants, 
such as goats and sheep; canine distemper virus (CDV), which causes distemper in dogs and a large 
number of other carnivore species; phocine distemper virus (PDV), which leads to distemper in several 
seal species and cetacean morbilliviruses (CeMV), which cause disease in dolphins and whales. As 
shown in Figure 1, all morbilliviruses are phylogenetically closely related [1,2]. Recently, a newly 
described virus of cats was named feline morbillivirus (FmoPV) [3]. Whether FmoPV is a “true” 
morbillivirus remains to be determined: Both molecular biology and inferred pathogenesis suggest that 
this is not the case. Finally, sequences of a morbillivirus endogenous to neotropical vampire bats were 
found in Brazil, potentially representing a new member of the genus Morbillivirus [4]. Yet again, the 
detection of short sequences does not equate to the presence of infectious virus, and efforts should be 
made to isolate pathogens where possible. 
 
Figure 1. An unrooted maximum likelihood phylogenetic tree of morbilliviruses was 
estimated under the general time-reversible model using PhyML software version 3.0 [5], 
using partial large (L) gene nucleotide sequences (GTR + I + G model). 
2. Measles 
Measles remains a significant cause of childhood morbidity and mortality in humans. The disease is 
characterized by fever, skin rash, cough and conjunctivitis, and a generalized immune suppression [6]. 
The resulting increased susceptibility to opportunistic infections may lead to life-threatening complications 
such as pneumonia and/or gastro-intestinal disease. Safe and effective live-attenuated virus vaccines have 
led to a substantial reduction in measles morbidity and mortality [7]. However, numbers of measles deaths 
have increased again in 2014, and measles resurgence may be imminent due to reduced measles vaccine 
acceptance in the industrialized world and budget deficits to maintain vaccination coverage in 














Within the Morbillivirus genus, MV is most closely related to RPV. It has been postulated that RPV or 
a closely related ancestral cattle virus crossed the species barrier into humans 1000–5000 years ago [2]. At 
the end of the 19th century, introduction of RPV into previously unexposed cattle resulted in catastrophic 
outbreaks, causing decimation of herds and famine in many African countries [9,10]. In consecutive 
decades, RPV had a devastating impact on cattle worldwide and the human populations that depended 
on them. Through the use of an efficacious vaccine rinderpest virus was declared globally eradicated in 
2011 [11]. 
PPRV is referred to as “the plague of small ruminants” and is a highly contagious and fatal disease for 
sheep and goats. Being closely related to RPV, and considering the importance of sheep and goats to farmers 
in Africa and South Asia, PPRV may also become a potential candidate for global eradication [12]. A 
comprehensive review of PPRV can be found in this special issue of Viruses [13]. 
4. Distemper 
Canine distemper has been described as an infectious disease of dogs since the 17th century, but CDV 
has the capacity to infect a wide range of carnivores. Since distemper is associated with high morbidity 
and mortality [14], most domestic carnivores are vaccinated. CDV infection can obliterate virtually all 
lymphocytes in a host, leading to severe immune suppression. Interestingly, from an epidemiologic point 
of view CDV is unlike any other morbillivirus, since it can be sustained in target species living in low-
density populations. In addition, the virus is renowned for its neurovirulence. Both characteristic aspects 
of this disease may be related to the severity of the immune suppression and the resulting prolonged 
virus shedding. A review of the pathogenesis of CDV leukoencephalitis can be found in this issue [15]. 
5. Marine Mammal Morbilliviruses 
PDV and CeMV, two phylogenetically distinct morbilliviruses, have caused significant disease 
outbreaks in marine mammals. PDV mainly infects seals, and two large outbreaks have been reported 
thus far. In 1988, approximately 18,000 harbor seals died in northwest Europe. A second, and equally 
devastating outbreak, occurred in the same area in 2002 [16]. Notably, disease outbreaks in seals in Lake 
Baikal in 1987 and in the Caspian Sea in 2000 were not attributed to PDV, but to CDV [17,18]. It is 
estimated that currently only 11% of the seals in Dutch coastal waters have PDV-specific antibodies, 
meaning that a re-introduction of PDV or CDV into this population could spark another outbreak with 
equivalent mass-mortality [19]. 
Over the last three decades CeMV has been responsible for large disease outbreaks among cetaceans, 
including harbor porpoises, striped dolphins, bottlenose dolphins, and pilot whales. Two comprehensive 
reviews of morbillivirus infections in seals and cetaceans can be found in this issue [20,21]. 
6. Other Morbilliviruses 
Recently, novel morbilliviruses were detected in felines and bats. FmoPV was first described in 2012 
as a morbillivirus of cats, and has thus far only been identified in China and Japan. Phylogenetically 
FmoPV is distantly related to the other morbilliviruses [3]. In addition, the pathogenesis of FmoPV is 
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different from the other morbilliviruses. FmoPV has been associated with tubulointerstitial nephritis, 
making it questionable whether FmoPV is a “true” morbillivirus. In Brazilian vampire bats two short 
morbillivirus polymerase sequences were discovered in 2012. However, no infectious virus has been 
isolated [4]. Whether these sequences represent novel morbilliviruses endemic among bat populations 
remains to be determined. 
7. Cellular Receptors and Cross-Species Infections 
Infection of cells by morbilliviruses is initiated by binding of the hemagglutinin (H) glycoprotein to 
cellular receptors. Two cellular receptors have been described for wild-type morbilliviruses: CD150 
(also known as signaling lymphocyte activation molecule F1 or SLAM/F1) in 2000 [22] and poliovirus 
receptor-like 4 (PVRL4, also known as nectin-4) in 2011 [23,24]. CD150 is mainly expressed on subsets 
of immune cells, while PVRL4 is expressed in epithelial cells. Since morbilliviruses can also infect cells 
of the central nervous system, additional receptors may exist. A review of the discovery of PVRL4 as 
cellular receptor for morbilliviruses can be found in this issue [25]. 
Interestingly, the phylogenetic relationships of the morbilliviruses largely parallel those of their 
respective host species [2,26]. The different morbilliviruses most likely evolved from a common 
ancestral virus that has adapted to their respective mammalian hosts, indicating that morbilliviruses have 
an intrinsic capacity to adapt to new host species [26]. This adaptation requires mutations in the 
morbillivirus receptor-binding H glycoprotein. The fact that the protein uses overlapping regions to bind 
to CD150 and PVRL4 [27] is likely a major hurdle for morbilliviruses to cross the species barrier. 
Of all the morbilliviruses CDV is the most promiscuous, infecting many different carnivore species. 
Even though initially less pathogenic in new carnivore hosts, the virus caused large disease outbreaks in 
phocids and felids [28]. CDV also has the capacity to cross the species barrier from carnivores into 
primates: Several CDV outbreaks in non-human primates have been reported [29,30] and therefore the 
virus also may poses a potential threat for morbillivirus-naive humans. However, morbilliviruses induce 
cross-protection [31], and measles vaccination provides protection against CDV infection [32]. 
8. Intervention Strategies 
Vaccination is the most effective intervention strategy to combat morbillivirus infections. 
Morbilliviruses are even considered as vectors for protection against other infectious diseases [33].  
In recent years antiviral compounds have also been developed as post-exposure prophylaxis for high-risk 
contacts of confirmed index cases [34]. Such compounds could also be considered for use in endangered 
or captive wildlife species. In particular, both pre- and post-exposure treatment of ferrets with an orally 
available small-molecule polymerase inhibitor showed efficacy against CDV infection in ferrets [35]. 
Similarly, fusion-inhibitory peptides were shown to inhibit or prevent MV infection in small animal 
models [36]. 
9. Oncolytic Virotherapy 
In recent years, MV has extensively been tested as a potential oncolytic virus [37]. These therapies 
either use the inherent lymphotropic nature of the virus, or try to retarget the virus to other cell types.  
Viruses 2015, 7 703 
 
 
In addition, PVRL4 is a well-known tumor-associated marker for several adenocarcinomas [25].  
Viruses can be reprogrammed to improve their oncolytic potential, referred to as targeting (introducing 
multiple layers of cancer specificity to improve safety and efficacy), arming (expression of prodrug 
convertases and cytokines) and shielding (protection from immune responses) [38]. Interestingly, 
morbillivirus provides substantial genetic flexibility due to their pleomorphic nature [39]. A review of 
the potential of CDV as an oncolytic virus can be found in this special issue [40]. 
10. Conclusions 
The identification of cellular receptors and improvement of animal models has provided important 
new insights into the pathogenesis of morbillivirus infections. It has become clear that all morbilliviruses 
initially infect cells of the immune system, before they spread to epithelial, endothelial and/or neuronal 
cells. Morbilliviruses remain a potential cause of disease outbreaks in previously unexposed populations. 
However, they can also be used to our advantage, as vaccine vectors or as oncolytic viruses. Sustained 
vaccination coverage and surveillance of circulating morbilliviruses will remain of critical importance 
for years to come [41]. 
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